Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities

Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis

(2015) Cecilia Arana Yi et al.   Future Oncology

Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors

(2014) L. Springuel et al.   BLOOD

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model

(2014) S. Degryse et al.   BLOOD

Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition

(2014) P. J. Lupardus et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia

(2013) D Bellanger et al.   LEUKEMIA

Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia

(2013) Hirotoshi Sakaguchi et al.   NATURE GENETICS

Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia

(2012) T Bains et al.   LEUKEMIA

Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy

(2012) Fumihiro Yamaguchi et al.   LUNG CANCER

Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors

(2011) Claude Haan et al.   CHEMISTRY & BIOLOGY

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

(2011) M. He et al.   CLINICAL CANCER RESEARCH

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors

(2011) T. Hornakova et al.   HAEMATOLOGICA

Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects

(2011) Ludovica Riera et al.   LEUKEMIA & LYMPHOMA

Structural Snapshots of Full-Length Jak1, a Transmembrane gp130/IL-6/IL-6Rα Cytokine Receptor Complex, and the Receptor-Jak1 Holocomplex

(2011) Patrick J. Lupardus et al.   STRUCTURE

Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ

(2010) Geoff M. Gordon et al.   BIOCHEMICAL JOURNAL

Identification of a Potent Janus Kinase 3 Inhibitor with High Selectivity within the Janus Kinase Family

(2010) Gebhard Thoma et al.   JOURNAL OF MEDICINAL CHEMISTRY

Array-based genomic resequencing of human leukemia

(2010) Y Yamashita et al.   ONCOGENE

Acute Lymphoblastic Leukemia-associated JAK1 Mutants Activate the Janus Kinase/STAT Pathway via Interleukin-9 Receptor α Homodimers

(2009) Tekla Hornakova et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes

(2008) G. Wernig et al.   BLOOD

The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia

(2008) Elizabeth Kudlacz et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Ligand-independent Homomeric and Heteromeric Complexes between Interleukin-2 or -9 Receptor Subunits and the γ Chain

(2008) Yaniv Malka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY